| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a linker molecule, m-PEG9-acid itself has no intrinsic biological activity; it serves as a structural connector to join a target protein ligand and an E3 ubiquitin ligase ligand in PROTAC synthesis. The PEG9 spacer provides a balance of hydrophilicity and flexibility, which can facilitate the formation of a productive ternary complex between the target protein, the PROTAC, and the E3 ligase. PEG linkers are known to improve the solubility, reduce aggregation, and extend the circulation half-life of bioconjugates. The terminal carboxylic acid allows for amide bond formation with amine-containing ligands using standard coupling reagents such as EDC and NHS. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final PROTAC molecule after conjugation with appropriate ligands. The in vivo efficacy of a complete PROTAC is determined in animal models.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95-98%. The molecular weight (456.53) is monodisperse and well-defined. The PEG9 chain is a discrete, single molecular weight species, as opposed to polydisperse PEG polymers.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing PROTACs. In a typical synthesis, the terminal carboxylic acid is activated with EDC and NHS and reacted with a primary amine-containing ligand (either a target protein ligand or an E3 ligase ligand). The resulting PROTAC conjugate is then tested in cells for target degradation activity. The hydrophilic PEG9 spacer is expected to improve the cellular permeability and solubility of the final PROTAC molecule.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete PROTAC conjugate, in vivo studies are conducted following institutional guidelines to evaluate its pharmacokinetic properties and efficacy. The PEG9 spacer may improve the circulation half-life and reduce immunogenicity of the PROTAC molecule compared to shorter PEG or alkyl linkers. The compound is typically formulated in a vehicle containing DMSO, PEG300, Tween-80, and saline for intraperitoneal (IP) or intravenous (IV) administration.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 456.53, a molecular formula of C20H40O11, and a standard purity of ≥95-98%. It appears as a solid at room temperature. The IUPAC name is 2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-oic acid, also known as mPEG8-propionic acid or mPEG8-CH2CH2COOH. For storage, it should be kept as a powder at -20degC for up to 3 years or in a solvent at -80degC for 6 months. It is soluble in DMSO and other organic solvents. The product should be protected from light and moisture during storage.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The product is stable under recommended storage conditions. It is not an approved therapeutic drug and has not been cleared for clinical use. It is a PROTAC linker used for research and development purposes only.
|
| References |
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
|
| Additional Infomation |
The 9-unit PEG spacer (PEG9) provides an intermediate-length hydrophilic linker that balances solubility and flexibility for constructing PROTACs. The well-defined, monodisperse nature of this PEG linker (as opposed to polydisperse PEG polymers) ensures batch-to-batch consistency and enables precise structure-activity relationship studies. This compound is also known as mPEG8-propionic acid and is commonly used in bioconjugation, drug delivery systems, polymer-drug conjugates, and protein modifications. The terminal carboxylic acid group enables versatile conjugation strategies, making this linker a valuable building block for PROTAC libraries and various chemical biology applications.
|
| Molecular Formula |
C20H40O11
|
|---|---|
| Molecular Weight |
456.525008201599
|
| Exact Mass |
456.257
|
| CAS # |
2576495-35-5
|
| PubChem CID |
58473367
|
| Appearance |
Colorless to light yellow liquid（Density：1.111 g/cm3）
|
| LogP |
-1.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
27
|
| Heavy Atom Count |
31
|
| Complexity |
358
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(CCOCCOCCOCCOC)CCOCCOCCOCCOCCC(=O)O
|
| InChi Key |
HVDSDOIAPZITDA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H40O11/c1-23-4-5-25-8-9-27-12-13-29-16-17-31-19-18-30-15-14-28-11-10-26-7-6-24-3-2-20(21)22/h2-19H2,1H3,(H,21,22)
|
| Chemical Name |
3-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1904 mL | 10.9522 mL | 21.9044 mL | |
| 5 mM | 0.4381 mL | 2.1904 mL | 4.3809 mL | |
| 10 mM | 0.2190 mL | 1.0952 mL | 2.1904 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
